Navigation Links
Arteriocyte Receives FDA Approval to Initiate Compartment Syndrome Trial for Amputation Prevention Focused on Wounded Warriors
Date:4/6/2012

CLEVELAND, April 6, 2012 /PRNewswire/ -- Arteriocyte, a leading biotechnology company with offices in Cleveland, Ohio and Hopkinton, Massachusetts announced today approval from the Food and Drug Administration (FDA) to initiate a Phase I clinical trial using its Magellan MAR01™ technology in the treatment of Compartment Syndrome. The FDA Investigational Device Exemption (IDE 15013) allows Arteriocyte and its clinical partners to initiate evaluation of concentrated marrow injections (using the Magellan MAR01™ technology) to mitigate ischemic damage due to Compartment Syndrome in extremity trauma patients. This treatment has been developed in partnership with the United States Army Institute of Surgical Research (ISR) and San Antonio Military Medical Center (SAMMC) at Fort Sam Houston, and The Ohio State University as part of Arteriocyte's Cellular Therapies for Battlefield Wounds Program.

The Magellan® system is an FDA 510(k) cleared medical device for the rapid production of platelet rich plasma from blood and bone marrow that can be applied to a surgical site as surgeons deem necessary for their clinical use requirements. Magellan MAR01™ technology enables the rapid Operating Room based "closed system" concentration of aspirated bone marrow, yielding an injectable tissue rich in platelets, hematopoietic stem cells and mesenchymal stem cells in as little as fifteen minutes. The self contained Magellan unit provides critical ease-of-use and operator-independent consistency necessary for deployment in military medical operations. Arteriocyte has partnered with the U.S. Military to develop Magellan MAR01™ in clinical use across three trauma platforms: Extremity Trauma, Burn Wounds and Infection Prevention. The company is already actively enrolling patients in a separate clinical trial for MAR01™ treatment in Critical Limb Ischemia under an FDA approved Investigational Device Exemption (IDE-14522).

The current clinical
'/>"/>

SOURCE Arteriocyte
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Arteriocyte Takes the Lead in Promoting Building Future Pipeline of Women in STEM Career Fields
2. Arteriocyte Receives $1 Million Award From Ohio Third Frontier Program to Advance Its NANEX™ Technology Toward Clinical Use
3. Arteriocyte and the U.S. Army Institute of Surgical Research (USAISR) Sign a CRADA to Speed Development of Cellular Therapies for Orthopaedic Trauma
4. Arteriocyte Receives FDA Approval to Move Forward with Critical Limb Ischemia Trial
5. Arteriocyte Named Top Biotech Start Up Venture by the Ohio Venture Association for 2010
6. Lixte Biotechnology Receives US Patent for Its Proprietary Histone Deacetylase Inhibitor
7. Rensselaer professor Jie Lian receives NSF CAREER Award
8. Islet Sciences Announces DiaKine Therapeutics Novel Diabetes, Atherosclerosis Drugs Receives European Patent Protection
9. Watsons Generic BONIVA® 150mg Receives FDA Approval
10. Cepheid Receives Grant to Develop Sample Processing and Amplification Methods for Detection of Bloodstream Bacteria
11. Foundation of UMDNJ Receives Grand Challenges Tuberculosis Biomarkers Grant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... and Cardiff, UK (PRWEB) January 13, 2014 ... development leader with more than 20 years in the ... optics and photonics . Hainsey will serve as the ... to have Dr. Hainsey join SPIE as our Technology ...
(Date:1/14/2014)... January 14, 2014 During the 1600’s through ... as “The Doctor’s Plague.” In this time period, doctors did ... led, at times, to the death of vulnerable patients. In ... know that they may be unwittingly transmitting herpes viruses to ...
(Date:1/14/2014)... NC (PRWEB) January 14, 2014 BioMedomics, ... on ultra-sensitive POC diagnostic platforms and novel disease specific POC ... round of financing netting a total of $690,000. The investment ... capital in the company. This group of private investors has ...
(Date:1/14/2014)... Panama (PRWEB) January 14, 2014 ... received the county’s first clinical trial approval for ... cord-derived mesenchymal stem cells (MSC) from the Comité ... Board (IRB). , Rheumatoid Arthritis (RA) is an ...
Breaking Biology Technology:Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3BioMedomics, Inc. Closes $690K Round of Financing 2Panama’s First Umbilical Cord Stem Cell Clinical Trial for Rheumatoid Arthritis Approved by Comité Nacional de Bioética de la Investigación Institutional Review Board 2Panama’s First Umbilical Cord Stem Cell Clinical Trial for Rheumatoid Arthritis Approved by Comité Nacional de Bioética de la Investigación Institutional Review Board 3
... , , CALGARY, Dec. ... company developing protein pharmaceuticals in crop plants, today announced ... of its plant-produced insulin with the first injection of ... the United Kingdom (UK), will include up to 30 ...
... numerous,shareholder inquiries, CEL-SCI Corporation (NYSE Alternext US: CVM) announced,today ... manufacturing facility to,its website. The pictures can be accessed ... link "Updated Pictures of,Manufacturing Facility" in the special highlights ... is developing its cancer product Multikine(R) for approval as ...
... FRANCISCO, Calif., Dec. 3 Portola,Pharmaceuticals, a biopharmaceutical ... cardiovascular disease, inflammatory disease,and cancer, today announced that ... that inhibit spleen tyrosine kinase (Syk) and its ... at the annual meeting of the,American Society of ...
Cached Biology Technology:SemBioSys begins phase I/II trial of insulin produced in plant seeds 2SemBioSys begins phase I/II trial of insulin produced in plant seeds 3Portola Data on Its Novel Syk Inhibitors and Novel Universal Factor Xa Inhibitor Antidote to be Presented at 2008 American Society of Hematology (ASH) Meeting 2Portola Data on Its Novel Syk Inhibitors and Novel Universal Factor Xa Inhibitor Antidote to be Presented at 2008 American Society of Hematology (ASH) Meeting 3
(Date:4/18/2014)... as they,re planted may be good news for a garden. ... wild, a plant whose seeds sprouted at the first ,warm ... an insurance policy against late frosts or unexpected dry spells, ... Plants whose seeds put off sprouting until conditions are ... team of researchers working at the National Evolutionary Synthesis Center ...
(Date:4/17/2014)... peptide inhibits RSV infection , Respiratory syncytial ... respiratory tract infections, generating life-threating illness in very ... therapies are limited. RSV enters host cells through ... six-helix fusogenic bundle. Small interfering peptides that prevent ... these peptides are highly susceptible to degradation. In ...
(Date:4/17/2014)... Gauthier and Professor Luca Razzari of the nergie ... large grants from the John R. Evans Leaders ... for the acquisition of state-of-the-art biotech and nanophotonics ... grants from the Ministre de l,Enseignement suprieur, de ... Technologie (MESRST). These new laboratories will help us ...
Breaking Biology News(10 mins):Plants with dormant seeds give rise to more species 2JCI online ahead of print table of contents for April 17, 2014 2JCI online ahead of print table of contents for April 17, 2014 3JCI online ahead of print table of contents for April 17, 2014 4JCI online ahead of print table of contents for April 17, 2014 5JCI online ahead of print table of contents for April 17, 2014 6New state-of-the-art biotech and nanotech equipment for INRS 2
... came from other planets. So concludes a major scientific article which ... Cosmology.com For thousands ... life. Surprisingly, most scientists and the Catholic Church are of the ... "organic soup." In the Judeo-Christian Bible, the ...
... Dental and tissue engineering researchers at Tufts University School of ... at Tufts have harnessed the pluripotency of human embryonic stem ... skin and the oral mucosa (the moist tissue that lines ... online in advance of print in Tissue Engineering Part ...
... scientists at Iowa State University,s Plant Sciences Institute has ... in plant genes much more efficient, practical and safe. ... associate scientist, and Jeffery Townsend, an assistant scientist, and ... have a huge impact on plant genetic work in ...
Cached Biology News:Life on Earth came from other planets 2Life on Earth came from other planets 3Life on Earth came from other planets 4Skin-like tissue developed from human embryonic stem cells 2Iowa State University researchers develop process for 'surgical' genetic changes 2Iowa State University researchers develop process for 'surgical' genetic changes 3
...
...
...
... Sepharose High Performance, 5 ml. The ... in HiTrap Streptavidin columns for fast, ... packing into Tricorn 5/50 GL, XK ... scale purifications are required.Extremely useful for ...
Biology Products: